$8.448
0.328[4.04%]
Last update: 10:48AM Get Real Time Here
Recursion Pharmaceuticals
(NASDAQ:RXRX)Recursion Pharmaceuticals Stock (NASDAQ:RXRX), Analyst Ratings, Price Targets, Predictions
Recursion Pharmaceuticals Inc has a consensus price target of $15.55, established from looking at the 38 latest analyst ratings. The last 3 analyst ratings were released from Needham, Keybanc, and Needham on April 9, 2024, March 4, 2024, and February 28, 2024. With an average price target of $16.67 between Needham, Keybanc, and Needham, there's an implied 97.29% upside for Recursion Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Keybanc
TD Cowen
JP Morgan
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Recursion Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/09/2024 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2024 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 89.39% | Keybanc | Scott Schoenhaus | $15 → $16 | Maintains | Overweight | Get Alert |
| 02/28/2024 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | $15 → $17 | Maintains | Buy | Get Alert |
| 01/26/2024 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | — | TD Cowen | Steven Mah | — | Initiates | → Market Perform | Get Alert |
| 01/17/2024 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 77.56% | Needham | Gil Blum | → $15 | Reiterates | Buy → Buy | Get Alert |
| 01/16/2024 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 77.56% | Needham | Gil Blum | → $15 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 18.37% | JP Morgan | Eric Joseph | $11 → $10 | Maintains | Neutral | Get Alert |
| 11/09/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 77.56% | Needham | Gil Blum | $17 → $15 | Maintains | Buy | Get Alert |
| 09/05/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/18/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/13/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 30.21% | Morgan Stanley | Vikram Purohit | $8 → $11 | Maintains | Equal-Weight | Get Alert |
| 07/13/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 77.56% | Keybanc | Scott Schoenhaus | $12 → $15 | Maintains | Overweight | Get Alert |
| 07/12/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 290.63% | Berenberg | Gal Munda | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | → Buy | Get Alert |
| 05/09/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 42.05% | Keybanc | Scott Schoenhaus | $20 → $12 | Maintains | Overweight | Get Alert |
| 04/18/2023 | RXRX | Buy Now | Recursion Pharmaceuticals | $8.45 | 101.23% | Needham | Gil Blum | → $17 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Recursion Pharmaceuticals (RXRX)?
The latest price target for Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on April 9, 2024. The analyst firm set a price target for $17.00 expecting RXRX to rise to within 12 months (a possible 101.23% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Recursion Pharmaceuticals (RXRX)?
The latest analyst rating for Recursion Pharmaceuticals (NASDAQ: RXRX) was provided by Needham, and Recursion Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Recursion Pharmaceuticals (RXRX)?
There is no last upgrade for Recursion Pharmaceuticals.
When was the last downgrade for Recursion Pharmaceuticals (RXRX)?
The last downgrade for Recursion Pharmaceuticals Inc happened on April 18, 2022 when B of A Securities changed their price target from N/A to N/A for Recursion Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Recursion Pharmaceuticals (RXRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Recursion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Recursion Pharmaceuticals was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.
Is the Analyst Rating Recursion Pharmaceuticals (RXRX) correct?
While ratings are subjective and will change, the latest Recursion Pharmaceuticals (RXRX) rating was a reiterated with a price target of $0.00 to $17.00. The current price Recursion Pharmaceuticals (RXRX) is trading at is $8.45, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.